MIT scientists just uncovered a hidden gut protein that traps and slays antibiotic-resistant killers, potentially rewriting the rules of infection defense forever.
Story Highlights
- Intelectin-2 binds bacterial sugars to immobilize and destroy pathogens like Staphylococcus aureus and Klebsiella pneumoniae.
- The protein reinforces the gut’s mucus barrier by crosslinking mucins, shielding against invasions.
- Published March 16, 2026, in Nature Communications, this dual-action discovery targets IBD and resistance crises.
- Led by Laura Kiessling at MIT, it leverages innate immunity over synthetic drugs.
- Broad efficacy promises cheaper, resistance-proof therapies grounded in the body’s own arsenal.
Intelectin-2’s Dual Antimicrobial Mechanism
MIT researchers identified intelectin-2, a lectin protein in the GI tract, that recognizes sugar molecules on bacterial membranes. This binding traps harmful bacteria, including resistant strains like Staphylococcus aureus and Klebsiella pneumoniae. The protein slows bacterial growth and triggers membrane disintegration. Experiments used biochemical assays to confirm these effects, revealing intelectin-2’s broad-spectrum power against GI pathogens.
Intelectin-2 also crosslinks mucin components in the gut’s protective mucus layer. This reinforcement prevents pathogen breaches during infections. The dual role addresses failures in IBD, where mucus instability heightens vulnerability. Prior lectin studies lacked this detailed structural and killing synergy, making intelectin-2 a breakthrough in mucosal defense.
Research Team and Experimental Breakthrough
Laura Kiessling, Novartis Professor of Chemistry at MIT, served as senior author directing the study. Lead authors Amanda Dugan, former research scientist, and Deepsing Syangtan, PhD student from 2024, conducted key experiments. Contributors included Charles Bevins from UC Davis School of Medicine and Ramnik Xavier from Harvard Medical School and Broad Institute. MIT hosted the primary work, fostering academic collaborations without commercial ties.
The team built on lectin biology through targeted assays. They demonstrated intelectin-2’s affinity for bacterial glycan motifs and mucins. Bacteria clustered upon binding, halting proliferation and causing rupture. These findings fill gaps in gut barrier science, especially amid global antibiotic resistance surges.
Publication and Expert Insights
The study appeared in Nature Communications on March 16, 2026, marking the story’s debut. Kiessling stated intelectin-2 operates in two ways: stabilizing mucus while neutralizing bacteria. She added harnessing human lectins opens new strategies against resistance. No post-publication updates exist yet, with focus turning to therapeutic applications.
Researchers praise the broad efficacy, suggesting designs for synthetic mucus reinforcers. The uniform expert view highlights innovation beyond narrow antibiotics. Bolstering natural defenses beats over-relying on drugs prone to failure.
MIT scientists discover gut protein that traps and kills dangerous bacteria https://t.co/ipYfIvMh4m
— Un1v3rs0 Z3r0 (@Un1v3rs0Z3r0) March 16, 2026
Short-term, intelectin-2 validates as an IBD biomarker and therapy target. Long-term, it enables resistance-bypassing antimicrobials, cutting GI infections. IBD patients and infection-prone individuals stand to benefit most. Economic gains include reduced drug development costs via host proteins. Biotech shifts toward host-derived solutions in gastroenterology.
Sources:
MIT Scientists Discover Gut Protein That Traps and Kills Dangerous Bacteria
Protein found in GI tract can neutralize many bacteria
Scientists Discover Natural Protein That Traps and Kills Harmful Bacteria
